Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

April 23, 2026

Study Completion Date

April 23, 2026

Conditions
Cystic Fibrosis
Interventions
DRUG

VX-828

Suspension for Oral Administration

DRUG

Placebo

Suspension for Oral Administration

DRUG

Itraconazole

Solution for Oral Administration

DRUG

Midazolam

Syrup for Oral Administration

DRUG

Tezacaftor

Tablets for Oral Administration

DRUG

VX-118

Tablets for Oral Administration

DRUG

Placebo

Suspension and Tablets for Oral Administration

DRUG

Deutivacaftor

Tablets for Oral Administration

DRUG

VX-828

Tablets for Oral Administration

Trial Locations (10)

10532

RECRUITING

New York Medical College, Hawthorne

32803

RECRUITING

Central Florida Pulmonary Group, P.A., Orlando

33021

RECRUITING

Joe DiMaggio Cycstic Fibrosis & Pulmonary Center, Hollywood

40508

RECRUITING

Kentucky Children's Hospital, Lexington

43606

RECRUITING

ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC, Toledo

55455

RECRUITING

University of Minnesota -Pulmonology, Minneapolis

66212

RECRUITING

Altasciences Clinical Kansas, Overland Park

76104

RECRUITING

Cook Children's Pulmonology, Fort Worth

02115

RECRUITING

Boston Children's Hospital, Boston

05446

RECRUITING

Vermont Lung Center, Colchester

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY